Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

被引：0
|
作者：
Kawachi, H. [1 ]
Tamiya, M. [1 ]
Tamiya, A. [2 ]
Ishii, S. [2 ]
Hirano, K. [3 ]
Matsumoto, H. [3 ]
Yokoyama, T. [4 ]
Ishida, T. [4 ]
Ryota, K. [5 ]
Fujimoto, D. [6 ]
Hosoya, K. [6 ]
Suzuki, H. [7 ]
Hirashima, T. [8 ]
Kanazu, M. [9 ]
Sawa, N. [10 ]
Uchida, J. [11 ]
Morita, M. [12 ]
Makio, T. [13 ]
Hara, S. [13 ]
Kumagai, T. [1 ]
机构：
[1] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan
[2] Kinki Chuo Chest Med Ctr, Internal Med, Sakai, Osaka, Japan
[3] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan
[4] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[5] Himeji Med Ctr, Resp Med, Himeji, Hyogo, Japan
[6] Kobe City Med Ctr Gen Hosp, Resp Med, Kobe, Hyogo, Japan
[7] Osaka Habikino Med Ctr, Thorac Oncol, Habikino, Japan
[8] Osaka Prefectural Habikino Hosp, Thorac Oncol, Habikino, Japan
[9] Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[10] Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[11] Osaka Gen Med Ctr, Resp Med, Osaka, Japan
[12] Kobe City Med Ctr West Hosp, Resp Med, Kobe, Hyogo, Japan
[13] Itami City Hosp, Resp Med, Itami, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1514P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [42] Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
    Dudnik, E.
    Moskovitz, M.
    Rottenberg, Y.
    Lobachov, A.
    Mandelboim, R.
    Shochat, T.
    Urban, D.
    Wollner, M.
    Nechushtan, H.
    Rotem, O.
    Zer, A.
    Bar, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S854 - S854
  • [43] Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study
    Xie, Jingyuan
    Xu, Ke
    Cai, Zijing
    Chen, Mo
    Jiang, Yuxin
    Ye, Jinjun
    Lin, Xinqing
    Lv, Tangfeng
    Zhan, Ping
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (03) : :526 - 539
  • [44] Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
    Shah, M.
    Marmarelis, M. E.
    Mamtani, R.
    Hubbard, R. A.
    Hennessy, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S369 - S370
  • [45] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
    Alessi, Joao, V
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizyi, Hira
    Carter, Brett W.
    Heymach, John, V
    Altan, Mehmet
    Hellmann, Matthew
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [46] Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
    Perea, J.
    Gomez, E.
    Escriva, C.
    Pellicer, A. V.
    Rodriguez, P. Llor
    Iranzo, J.
    Vidal, O. J. Juan
    Sanchez, J. Garcia
    Montagud, G. Suay
    Mico, A. Ferrero
    Diaz, J. Linares
    Sepulveda, N. Gomez
    Hernandez, E. Soria
    Gallego, J. Esteve
    Carrasco, C.
    Gaudens, P. Capdevila
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S72 - S73
  • [47] Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%
    Frost, Nikolaj
    Ghori, Razi
    Roy, Ananya
    Nunes, Ana Tablante
    Yang, James Chih-Hsin
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab
    Yamaguchi, Ou
    Kaira, Kyoichi
    Shinomiya, Shun
    Mouri, Atsuto
    Hashimoto, Kosuke
    Shiono, Ayako
    Miura, Yu
    Akagami, Tomoe
    Imai, Hisao
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    THORACIC CANCER, 2021, 12 (03) : 304 - 313
  • [49] Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
    Florian Eude
    Florian Guisier
    Mathieu Salaün
    Luc Thiberville
    Thibault Pressat-Laffouilhere
    Pierre Vera
    Pierre Decazes
    Annals of Nuclear Medicine, 2022, 36 : 224 - 234
  • [50] Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
    Eude, Florian
    Guisier, Florian
    Salaun, Mathieu
    Thiberville, Luc
    Pressat-Laffouilhere, Thibault
    Vera, Pierre
    Decazes, Pierre
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (03) : 224 - 234
12345